ClinicalTrials.gg
RecruitingNCT07175285BENCHMARK-SLEUpdated Nov 2, 2026

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

An observational study in Systemic Lupus Erythematosus (SLE), sponsored by Bristol-Myers Squibb. Recruiting at 70 sites in 13 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 2, 20267 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
223
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.

Started
2025
with 2 others
Observational
Only one
of the 20
Registered
18th of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is one of 3 that started in 2025, is the only observational one, and was the 18th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Systemic lupus erythematosus (SLE)
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include individuals diagnosed with systemic lupus erythematosus (SLE) with inadequate response (a lack of response, insufficient response, or lack of sustained response after at least 3-month treatment with appropriate doses of a standard of care therapy) to glucocorticoids and at least two immunosuppressants according to routine clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have signed and dated an Institutional Review Board/ Independent Ethics Committee (IRB/IEC)-approved written form (ICF) in accordance with regulatory, local, and institutional guidelines
  • Participants must be ≥16 years of age at the time of signing the ICF
  • Meet the European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE)
  • Have an inadequate response to and ≥ 2 therapies, one of which is a biologic therapy consistent with treatment guidelines, used for at least 3 months each. Eligibility is regardless of prior hydroxychloroquine or any anti-malarial treatment. Inadequate response is defined as a lack of response, insufficient response, or lack of sustained response after at least 3-month treatment with appropriate doses of a standard of care agent. Intolerance or may be considered as inadequate response provided it is documented and confirmed acceptable by the Adjudication Committee
  • Have active disease at study entry when signing ICF, defined as:

    • ≥ 1 British Isles Lupus Assessment Group Index (BILAG) A OR ≥ 1 BILAG B with history of SLE manifestations that would qualify for a BILAG A within the last 24 months, AND
    • Positive autoantibodies (at least one) to confirm diagnosis of SLE: Antinuclear antibody ≥1:160, anti-dsDNA, anti-Sm, anti-Ro (SSA), anti-La (SSB), or low complement proteins (C3 or C4)
  • Participants with lupus nephritis (LN) meeting the study eligibility criteria must have had a renal per standard of care within 6 months (± 30 days) prior to signing the ICF, indicating the presence of active Class III or IV LN (alone or in combination with Class V) according to the 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS), with \< 60% interstitial fibrosis and tubular atrophy \< 60% global glomerulosclerosis

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Participants enrolled in concurrent interventional clinical trials involving therapies or any other clinical trial
  • Participant is unwilling or unable to comply with routine clinical follow-up necessary for collection of study data
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
223 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Participants with systemic lupus erythematosus (SLE), including Lupus Nephritis, with inadequate response to glucocorticoids and at least 2 immunosuppressants, receiving current standard of care treatment options.

    Drug: Current standard of care treatment options

Interventions

  • DrugCurrent standard of care treatment options

    According to the product label

06

What researchers measure

Primary outcomes

  1. Number of of participants achieving Definition of Remission in Systemic Lupus Erythematosus (DORIS) at 6 months along with the 95% CI.

    Time frame: 6 months

Secondary outcomes

  1. Number of participants achieving drug-free Definition of Remission in Systemic Lupus Erythematosus (DORIS) remission

    Time frame: At 12, 24, 36, 48, and 60 months

  2. Complete renal response (CRR) for participants with baseline lupus nephritis (LN)

    Time frame: At 6, 12, 24, 36, 48, and 60 months

  3. Lupus-Low Disease Activity State (LLDAS) for participants with baseline Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAI) ≥ 6

    Time frame: At 12, 24, 36, 48, and 60 months

  4. Incidence and severity of flares, as assessed by Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAI) index

    Time frame: Up to 60 months

  5. SLE Responder Index 4 (SRI-4) for participants with baseline Lupus Erythematosus Disease Activity Questionnaire (SLEDAI) ≥ 6

    Time frame: At 6, 12, 24, 36, 48, and 60 months

  6. Change from baseline in proteinuria and estimated glomerular filtration rate (eGFR) - of those with high proteinuria and low eGFR

    Time frame: At 6, 12, 24, 36, 48, and 60 months

  7. Change in 2012 Systemic Lupus Collaborating Clinics Criteria for SLE (SLICC) / America College of Rheumatology (ACR) Damage Index (SDI) from baseline

    Time frame: At 12, 24, 36, 48, and 60 months

  8. Number of participants that maintain remission status as assessed by DORIS, LLDAS, and SRI-4

    Definition of Remission in Systemic Lupus Erythematosus (DORIS), Lupus-Low Disease Activity State (LLDAS) and SLE Responder Index 4 (SRI-4)

    Time frame: At 6, 12, 24, 36, 48, and 60 months

  9. Duration of treatment response

    Time frame: Up to 60 months

  10. Time to treatment response

    Time frame: Up to 60 months

  11. Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) patient reported outcome (PRO) from baseline

    Time frame: Baseline, and at 6, 12, 24, 36, 48, and 60 months

07

Study locations

53 of 70 sites recruiting
  • Local Institution - 0054
    La Jolla, California 92093, United States
    Not yet recruiting
    • Site 0054 · Contact
  • Local Institution - 0001
    La Palma, California 90623-1730, United States
    Not yet recruiting
    • Site 0001 · Contact
  • Local Institution - 0071
    Los Angeles, California 90095, United States
    Not yet recruiting
    • Site 0071 · Contact
  • Rheumatology Center of San Diego
    San Diego, California 92128-2551, United States
    Recruiting
    • Tania Rivera, Site 0035 · Contact858-336-2810
  • Centre for Rheumatology, Immunology and Arthritis
    Fort Lauderdale, Florida 33309-1715, United States
    Recruiting
    • Yvonne Sherrer, Site 0063 · Contact954-229-0425
  • South Florida Rheumatology
    Hollywood, Florida 33021-6052, United States
    Recruiting
    • Gizem Gokalp, Site 0061 · Contact954-961-3252
  • LIFE Clinical Trials
    Margate, Florida 33063, United States
    Recruiting
    • Jigar Shah, Site 0006 · Contact786-674-8868
  • One- Rheumatology
    Palm Beach Gardens, Florida 33410, United States
    Recruiting
    • Clifford Stermer, Site 0068 · Contact561-559-1110
  • Local Institution - 0069
    Atlanta, Georgia 30322-1013, United States
    Not yet recruiting
    • Site 0069 · Contact
  • Willow Rheumatology & Wellness
    Willowbrook, Illinois 60527, United States
    Recruiting
    • Angela Crowley, Site 0065 · Contact972-432-6708
  • Arthritis & Rheumatism Associates
    Rockville, Maryland 20850, United States
    Recruiting
    • Evan Siegel, Site 0064 · Contact301-942-6610
  • University of Michigan
    Ann Arbor, Michigan 48109-5000, United States
    Recruiting
    • Jacqueline Madison, Site 0034 · Contact734-764-2224
  • AA MRC
    Grand Blanc, Michigan 48439-2451, United States
    Recruiting
    • Ali Karrar, Site 0030 · Contact810-667-0067
  • Local Institution - 0070
    Kalispell, Montana 59901-3129, United States
    Not yet recruiting
    • Site 0070 · Contact
  • Sahni Rheumatology & Therapy
    West Long Branch, New Jersey 07764, United States
    Recruiting
    • KIREN SAHNI, Site 0060 · Contact732-272-1456
  • Kings County Hospital Center - Brooklyn
    Brooklyn, New York 11203, United States
    Recruiting
    • Alexander Feoktistov, Site 0039 · Contact520-834-8259
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28211, United States
    Recruiting
    • Charles Withers, Site 0026 · Contact704-247-9179
  • Local Institution - 0037
    Durham, North Carolina 27710-1000, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104-5005, United States
    Recruiting
    • Cristina Arriens, Site 0019 · Contact405-271-7805
  • Local Institution - 0075
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
    • Site 0075 · Contact
  • Local Institution - 0052
    Philadelphia, Pennsylvania 19140, United States
    Not yet recruiting
    • Site 0052 · Contact
  • Murfreesboro Medical Clinic
    Murfreesboro, Tennessee 37128, United States
    Recruiting
    • Marcus Owen, Site 0067 · Contact
  • Arthritis Care of Texas - Corpus Christi
    Corpus Christi, Texas 78415, United States
    Recruiting
    • Eric Chiang, Site 0066 · Contact361-400-7700
  • Lone Star Arthritis & Rheumatology Associates, P.C.
    Denton, Texas 76205, United States
    Recruiting
    • Michelle Luciano, Site 0062 · Contact480-400-8502
  • El Paso Medical Research Institute (MedResearch, Inc)
    El Paso, Texas 79902-4821, United States
    Recruiting
    • German Hernandez, Site 0027 · Contact915-544-4572
  • Local Institution - 0051
    Van Vleck, Texas 77482, United States
    Not yet recruiting
    • Site 0051 · Contact
  • Instituto Médico CER
    Quilmes, Buenos Aires B1878DVB, Argentina
    Recruiting
    • Alejandro Benitez, Site 0009 · Contact541152633113
  • Centro de Investigaciones Medicas Tucuman
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
    Recruiting
    • Walter Spindler, Site 0029 · Contact+54-9-381-5537820
  • Organización Médica de Investigación (OMI)
    Buenos Aires, C1015ABO, Argentina
    Recruiting
    • Joaquin Martinez Serventi, Site 0050 · Contact
  • Instituto De Reumatologia - IR Medical Center - Hospital de Dia
    Mendoza, M5500CPH, Argentina
    Recruiting
    • Marcos Alfredo Borgia, Site 0008 · Contact+54155440980
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Recruiting
    • Odirlei Monticielo, Site 0005 · Contact51996526170
  • LMK Servicos Medicos SS
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
    Recruiting
    • Mauro Keiserman, Site 0016 · Contact+5551998089284
  • Hospital Sao Lucas da PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
    Recruiting
    • Tatiana Karenini Muller, Site 0007 · Contact+555133142897
  • Local Institution - 0042
    São Paulo, 05403-000, Brazil
    Not yet recruiting
    • Site 0042 · Contact
  • Alberta Health Services (AHS) - Richmond Road Diagnostic and Treatment Centre
    Calgary, Alberta T2T 5C7, Canada
    Recruiting
    • Ann Clarke, Site 0003 · Contact403-210-8786
  • Centre hospitalier de l'Université Laval
    Calgary, Alberta T2T 5C7, Canada
    Recruiting
    • Paul Fortin, Site 0018 · Contact4166035753
  • St. Joseph's Hospital
    London, Ontario N6A 4V2, Canada
    Recruiting
    • Janet Pope, Site 0020 · Contact519 646 6332
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Catherine Ivory, Site 0021 · Contact
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
    Recruiting
    • Zahi Touma, Site 0004 · Contact41660358005743
  • Local Institution - 0038
    Sherbrooke, Quebec J1G 2E8, Canada
    Not yet recruiting
    • Site 0038 · Contact
  • CHU Hopitaux de Bordeaux - Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
    Recruiting
    • Christophe RICHEZ, Site 0023 · Contact0556794919
  • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
    Strasbourg, 67098, France
    Recruiting
    • Marc SCHERLINGER, Site 0024 · Contact0388127954
  • Hôpital Saint-Antoine
    Paris, Île-de-France Region 75012, France
    Recruiting
    • Amir Adedjouma, Site 0044 · Contact
  • Local Institution - 0041
    Kiel, Schleswig-Holstein 24105, Germany
    Not yet recruiting
    • Site 0041 · Contact
  • Local Institution - 0043
    Mainz, 55131, Germany
    Not yet recruiting
    • Site 0043 · Contact
  • Meir Medical Center
    Kfar Saba, M 4428164, Israel
    Recruiting
    • Shaye Kivity, Site 0012 · Contact
  • Sheba Medical Center
    Ramat Gan, TA 5262000, Israel
    Recruiting
    • Merav Lidar, Site 0031 · Contact97235302156
  • Rambam Medical Center
    Haifa, 31096, Israel
    Recruiting
    • Yolanda Braun-Moscovici, Site 0011 · Contact+97248542013
  • Carmel Medical Center
    Haifa, 34362, Israel
    Recruiting
    • Devy Zisman, Site 0036 · Contact+97248260213
  • Rabin Medical Center - Hasharon Hospital
    Petah Tikva, 4941492, Israel
    Recruiting
    • Ari Polachek, Site 0022 · Contact972039377077
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
    Recruiting
    • Tali Eviatar Shua, Site 0025 · Contact972524266984
  • Università degli Studi di Padova
    Padova, PD 35128, Italy
    Recruiting
    • margherita zen, Site 0017 · Contact00393492832723
  • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
    Ferrara, RE 44124, Italy
    Recruiting
    • Alessandra Bortoluzzi, Site 0040 · Contact+390532239651
  • Azienda Ospedaliera Ordine Mauriziano di Torino
    Torino, TO 10128, Italy
    Recruiting
    • Mariele Gatto, Site 0014 · Contact+390498275111
  • ASST degli Spedali Civili di Brescia
    Brescia, 25123, Italy
    Recruiting
    • Micaela Fredi, Site 0015 · Contact+390303995487
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
    Recruiting
    • Hiroshi Fujii, Site 0053 · Contact81227177000
  • Toyama University
    Toyama, Toyama 930-0887, Japan
    Recruiting
    • Masaru Kato, Site 0010 · Contact+81-76-434-7287
  • Hospital of the University of Occupational and Environmental Health, Japan
    Kitakyushu-Shi, 807-8556, Japan
    Recruiting
    • Satoshi Kubo, Site 0049 · Contact093-603-1611
  • Wakayama Medical University Hospital
    Wakayama, 641-8510, Japan
    Recruiting
    • Takao Fujii, Site 0055 · Contact+81-73-441-0875
  • Local Institution - 0046
    San Juan, PR 00917-3104, Puerto Rico
    Not yet recruiting
    • Site 0046 · Contact
  • Hospital de Merida
    Mérida, Badajoz 6800, Spain
    Recruiting
    • Raul Veroz Gonzalez, Site 0047 · Contact+34924381000
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Ignasi Rodriguez Pinto, Site 0048 · Contact+34607573229
  • Local Institution - 0072
    Lund, Skåne County SE-221 85, Sweden
    Not yet recruiting
    • Site 0072 · Contact
  • Local Institution - 0073
    Solna, Stockholm County 171 64, Sweden
    Not yet recruiting
    • Site 0073 · Contact
  • Local Institution - 0074
    Örebro, 701 85, Sweden
    Not yet recruiting
    • Site 0074 · Contact
  • Oxford University Hospitals NHS Trust - Churchill Hospital
    Oxford, OXF OX3 7LE, United Kingdom
    Recruiting
    • Anthony Psarras, Site 0056 · Contact+441865270000
  • Royal National Hospital for Rheumatic Diseases-Bath
    Bath, SOM BA1 3NG, United Kingdom
    Recruiting
    • Sarah Skeoch, Site 0058 · Contact
  • The Royal Wolverhampton NHS Trust - New Cross Hospital
    Wolverhampton, West Midlands WV10 0QP, United Kingdom
    Recruiting
    • Thomas Sheeran, Site 0045 · Contact441213532444
  • The Royal Free London NHS Foundation Trust - The Royal Free Hospital
    London, NW3 2QG, United Kingdom
    Recruiting
    • Shahir Hamdulay, Site 0059 · Contact+2077940500
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
    Recruiting
    • Jonathan Dick, Site 0057 · Contact
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

Of 112 observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 126. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartActual
Oct 8, 2025
Primary completionEst.
Mar 24, 2028
CompletionEst.
Oct 5, 2032
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 3 sites removed
Show 7 added (2 Brazil, 2 Canada, 1 United States, 1 Israel, 1 Italy)
  • University of Michigan · Ann Arbor, United States
  • LMK Servicos Medicos SS · Porto Alegre, Brazil
  • Hospital Sao Lucas da PUCRS · Porto Alegre, Brazil
  • Alberta Health Services (AHS) - Richmond Road Diagnostic and Treatment Centre · Calgary, Canada
  • Toronto Western Hospital · Toronto, Canada
  • Tel Aviv Sourasky Medical Center · Tel Aviv, Israel
  • Università degli Studi di Padova · Padova, Italy
Show 3 removed
  • Local Institution - 0034 · Ann Arbor, United States
  • Local Institution - 0007 · Porto Alegre, Brazil
  • Local Institution - 0025 · Tel Aviv, Israel
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    7 sites added, 3 sites removed
    Show 7 added (2 Brazil, 2 Canada, 1 United States, 1 Israel, 1 Italy)
    • University of Michigan · Ann Arbor, United States
    • LMK Servicos Medicos SS · Porto Alegre, Brazil
    • Hospital Sao Lucas da PUCRS · Porto Alegre, Brazil
    • Alberta Health Services (AHS) - Richmond Road Diagnostic and Treatment Centre · Calgary, Canada
    • Toronto Western Hospital · Toronto, Canada
    • Tel Aviv Sourasky Medical Center · Tel Aviv, Israel
    • Università degli Studi di Padova · Padova, Italy
    Show 3 removed
    • Local Institution - 0034 · Ann Arbor, United States
    • Local Institution - 0007 · Porto Alegre, Brazil
    • Local Institution - 0025 · Tel Aviv, Israel
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07175285
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Oct 8, 2025
Primary completion
Mar 24, 2028 (estimated)
Completion
Oct 5, 2032 (estimated)
Last update
Nov 2, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion